Table 2

 Clinical features and immunological findings in patients with limbic encephalitis seen at the Hospital of the University of Pennsylvania (n = 17)

Aza, azathioprine; CI, complete improvement; CTX, cyclophosphamide; F, female; IVIg, intravenous immunoglobulin; M, male; nCMAg, novel cell-membrane antigen; PI, partial improvement; PEX, plasma exchange; SCLC, small-cell lung cancer; VGKC, voltage -gated potassium channels; WBC, white blood cells.
*WBC (white cell count) per μl; normal value <4/μl.
†Prot (protein concentration) in mg/dl; normal value 16–46 mg/dl.
‡Other: fluid attenuation inversion recovery or T2 abnormalities in regions other than medial temporal lobes.
Total patients (antigen) Sex; age range (median), years Other neurological features or symptoms CSF findings, range (median) Typical “limbic” MRI abnormality Cancer Immunotherapy other than corticosteroids Neurological outcome
Hu, n = 4; Ma2, n = 1; atypical, n = 15M, 1F; 28–65 (63)Encephalomyelitis, n = 2; sensory neuronopathy, n = 3; 2 cerebellar/or brainstem, n = 2*WBC 0–81 (3); †Prot 74–150 (79)Typical, n = 4; other, n = 2‡SCLC, n = 4; testicular, n = 1; thyroid, n = 1IVIg, n = 1; CTX, n = 2;IVIg+PEX +Rituximab+Aza, n = 1PI (Ma2), n = 1; stable (Hu), n = 1;died, n = 4
nCMAg, n = 55F; 24–65 (44)Diffuse encephalitis, n = 2; decreased level of consciousness and hypoventilation, n = 1; chorea/dystonia, n = 1WBC 15–49 (30); Prot 18–97 (67)‡Other, n = 4; normal, n = 1Teratoma, n = 3 (ovary, n = 2; thymus, n = 1); cancer of thymus, n = 1; no tumour, n = 1IVIg, n = 1; PEX, n = 1;IVIg+PEX, n = 1CI (n = 4, teratoma, n = 3, cancer of thymus, n = 1); deteriorated (no tumour), n = 1
VGKC, n = 32M, 1F; 38–60 (58)Peripheral nerve hyperexcitability, n = 1WBC 0–4 (2); Prot 45–79 (63)Typical, n = 3Prostate, n = 1IVIg, n = 2CI, n = 2; stable, n = 1
No antibodies, n = 31M, 2F; 28–60 (40)Multiple (cerebellar myelopathy neuropathy), n = 1WBC 2–119 (10); Prot 32–132 (47)Typical, n = 2; other, n = 1Prostate, n = 1Aza, n = 1CI, n = 3